Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical TrialLeticia Rosario Cruz, Carmen Valenzuela, Raúl Santana et al.|ACS Pharmacology & Translational Science|2020Cited by 45
CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell ModelGeorge Perez, Silvio E. Perea|Biomedicines|2022Cited by 11
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical TrialLeticia Rosario Cruz, Idania Baladrón, Aliusha Rittoles et al.|medRxiv|2020Cited by 5